Difference between revisions of "Novavax"
(stub) |
(logo+) |
||
| Line 2: | Line 2: | ||
|wikipedia=https://en.wikipedia.org/wiki/Novavax | |wikipedia=https://en.wikipedia.org/wiki/Novavax | ||
|sourcewatch= | |sourcewatch= | ||
| − | |constitutes= | + | |constitutes=Spooky military-connected biotechnology company |
| − | |logo= | + | |logo=Novavax logo.png |
| + | |titular_logo=1 | ||
|start=1987 | |start=1987 | ||
|description= | |description= | ||
| Line 10: | Line 11: | ||
|founders= | |founders= | ||
|num_staff= | |num_staff= | ||
| − | |members= | + | |members=John C. Jacobs,James F. Young,Gregg Alton,Richard Douglas,Rachel King,Margaret G. McGlynn,David Mott,Rick Rodgers,Michael A. McManus,Rahul Singhvi,Stanley Erck,Bror Morein,Richard F. Maradie,Brenda L. Fugagli,Bennett Kaufman,Richard J. Harwood,Thomas G. Tachovsky,Craig Wright,John Otho Marsh Jr |
}} | }} | ||
'''Novavax, Inc.''' is an American biotechnology company. | '''Novavax, Inc.''' is an American biotechnology company. | ||
| + | |||
| + | ==History== | ||
| + | Already in 1998, the company had cooperation with the [[Defense Advanced Research Projects Agency]] for "Counter measures against Biological Warfare agents".<ref name=archive98>https://web.archive.org/web/19980611195113/http://www.novavax.com/</ref> | ||
| + | |||
| + | In [[2001]], Novavax arranged for an informal briefing in Congress, led by Congressman [[Curt Weldon]] (R-Pa), along with [[Roscoe Bartlett]], R-Md.; [[Joseph Hoeffel]], D-Pa.; and [[Connie Morella]], R-Md., who signed a "Dear Colleague" letter asking members of Congress to attend the briefing. In the briefing, [[Roger Pomerantz]], director of the Center for Human Virology at [[Thomas Jefferson University]], said the government should spend what it takes to find a new, safer [[smallpox]] vaccine that could be given to the entire population. The briefing came after the [[Department of Health and Human Services]] signed a contract with British firm [[Acambis]] to produce 290 million doses of a live-virus smallpox vaccine. The one under development by Acambis causes side effects that range from swollen arms to death.<ref>https://web.archive.org/web/20080929003220/https://www.usatoday.com/news/health/bioterrorism/2001-12-06-smallpox.htm</ref> | ||
| + | |||
| + | Prior to 2020, company scientists developed experimental vaccines for [[influenza]] and [[respiratory syncytial virus]] (RSV), as well as [[Ebola]] and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its "vaccine" for [[COVID-19]].<ref>Novavax Inc. [https://www.novavax.com/sites/default/files/2021-05/NVAX_2020_Annual_Report_FINAL.pdf 2020 Annual Report] {{Webarchive|url=https://web.archive.org/web/20210814001719/https://www.novavax.com/sites/default/files/2021-05/NVAX_2020_Annual_Report_FINAL.pdf |date=14 August 2021 }}. Accessed 10 May 2021.</ref> In 2021, it received the governments’s largest vaccine contract, despite it had never brought a vaccine to market in its 33-year history.<ref>https://www.nytimes.com/2020/07/16/health/coronavirus-vaccine-novavax.html</ref> | ||
| + | |||
| + | ==People== | ||
| + | Board as of 2024<ref>https://www.novavax.com/who-we-are/leadership#executive-leadership</ref>, plus some older associates.<ref>https://aibn.uq.edu.au/dr-rahul-singhvi</ref><ref>https://www.zippia.com/novavax-careers-8313/history/#</ref><ref name=archive98/> | ||
{{SMWDocs}} | {{SMWDocs}} | ||
==References== | ==References== | ||
{{reflist}} | {{reflist}} | ||
{{stub}} | {{stub}} | ||
Revision as of 03:54, 7 March 2024
.jpg){kind=small}
Novavax, Inc. is an American biotechnology company.
Contents
History
Already in 1998, the company had cooperation with the Defense Advanced Research Projects Agency for "Counter measures against Biological Warfare agents".[1]
In 2001, Novavax arranged for an informal briefing in Congress, led by Congressman Curt Weldon (R-Pa), along with Roscoe Bartlett, R-Md.; Joseph Hoeffel, D-Pa.; and Connie Morella, R-Md., who signed a "Dear Colleague" letter asking members of Congress to attend the briefing. In the briefing, Roger Pomerantz, director of the Center for Human Virology at Thomas Jefferson University, said the government should spend what it takes to find a new, safer smallpox vaccine that could be given to the entire population. The briefing came after the Department of Health and Human Services signed a contract with British firm Acambis to produce 290 million doses of a live-virus smallpox vaccine. The one under development by Acambis causes side effects that range from swollen arms to death.[2]
Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its "vaccine" for COVID-19.[3] In 2021, it received the governments’s largest vaccine contract, despite it had never brought a vaccine to market in its 33-year history.[4]
People
Board as of 2024[5], plus some older associates.[6][7][1]
Known members
2 of the 19 of the members already have pages here:
| Member | Description |
|---|---|
| John Otho Marsh | |
| Michael McManus | Deep state actor connected to the Octopus and Novavax. |
References
- ↑ a b https://web.archive.org/web/19980611195113/http://www.novavax.com/
- ↑ https://web.archive.org/web/20080929003220/https://www.usatoday.com/news/health/bioterrorism/2001-12-06-smallpox.htm
- ↑ Novavax Inc. 2020 Annual Report Archived 14 August 2021 at the Wayback Machine.. Accessed 10 May 2021.
- ↑ https://www.nytimes.com/2020/07/16/health/coronavirus-vaccine-novavax.html
- ↑ https://www.novavax.com/who-we-are/leadership#executive-leadership
- ↑ https://aibn.uq.edu.au/dr-rahul-singhvi
- ↑ https://www.zippia.com/novavax-careers-8313/history/#
